These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17459368

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide.
    Klinge JM, Topf HG, Trusen B, Rauh M, Rascher W, Dötsch J.
    Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397
    [Abstract] [Full Text] [Related]

  • 3. Augmentation of U46619 induced human platelet aggregation by aspirin.
    Kim JM, Koo YK, Jin J, Lee YY, Park S, Yun-Choi HS.
    Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
    [Abstract] [Full Text] [Related]

  • 4. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S, Krauze-Brzósko K, Manarini S, Evangelista V, Cerletti C.
    Eur J Pharmacol; 2004 Mar 19; 488(1-3):79-83. PubMed ID: 15044038
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca2+ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation.
    Kälvegren H, Skoglund C, Helldahl C, Lerm M, Grenegård M, Bengtsson T.
    Thromb Haemost; 2010 Feb 19; 103(2):398-407. PubMed ID: 20024498
    [Abstract] [Full Text] [Related]

  • 7. Platelet aggregating response to platelet activating factor participates in activation of the 12-lipoxygenase pathway in platelets from rabbits.
    Michibayashi T.
    Int Angiol; 2002 Sep 19; 21(3):260-7. PubMed ID: 12384648
    [Abstract] [Full Text] [Related]

  • 8. Calcium-dependent synergistic interaction of platelet activating factor and epinephrine in human platelet aggregation.
    Saeed SA, Rasheed H.
    Acta Pharmacol Sin; 2003 Jan 19; 24(1):31-6. PubMed ID: 12511226
    [Abstract] [Full Text] [Related]

  • 9. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM, Reininger AJ, Toth O, Deckmyn H, Brandl R, Siess W.
    Thromb Haemost; 2007 Mar 19; 97(3):435-43. PubMed ID: 17334511
    [Abstract] [Full Text] [Related]

  • 10. Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways.
    Lauri D, Cerletti C, de Gaetano G.
    J Lab Clin Med; 1985 Jun 19; 105(6):653-8. PubMed ID: 3923145
    [Abstract] [Full Text] [Related]

  • 11. Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation: a causal role in cardiovascular disease?
    Kälvegren H, Majeed M, Bengtsson T.
    Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1677-83. PubMed ID: 12842841
    [Abstract] [Full Text] [Related]

  • 12. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
    Storey RF, May JA, Heptinstall S.
    Thromb Res; 2005 Sep 01; 115(4):301-7. PubMed ID: 15668190
    [Abstract] [Full Text] [Related]

  • 13. The rabbit lens epithelial cell line N/N1003A requires 12-lipoxygenase activity for DNA synthesis in response to EGF.
    Haque MS, Arora JK, Dikdan G, Lysz TW, Zelenka PS.
    Mol Vis; 1999 Jun 15; 5():8. PubMed ID: 10369846
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity.
    Hernandez MR, Tonda R, Pedreño J, Salas E, Arderiu G, Pino M, Serradell M, Escolar G.
    J Cardiovasc Med (Hagerstown); 2006 Dec 15; 7(12):859-65. PubMed ID: 17122671
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2).
    Ikemoto S, Sugimura K, Kuratukuri K, Nakatani T.
    Anticancer Res; 2004 Dec 15; 24(2B):733-6. PubMed ID: 15161019
    [Abstract] [Full Text] [Related]

  • 17. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage.
    Hsiao G, Lin KH, Chang Y, Chen TL, Tzu NH, Chou DS, Sheu JR.
    Arterioscler Thromb Vasc Biol; 2005 Sep 15; 25(9):1998-2004. PubMed ID: 15976325
    [Abstract] [Full Text] [Related]

  • 18. Modulation of platelet and leucocyte function by a Chinese herbal formulation as compared with conventional antiplatelet agents.
    Zhao L, Gaudry L, Dunkley S, Brighton T, Guo ZX, Ye ZL, Luo RZ, Chesterman CN.
    Platelets; 2008 Feb 15; 19(1):24-31. PubMed ID: 18231935
    [Abstract] [Full Text] [Related]

  • 19. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
    Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, Magnusson O, Stefansson K, Hartman D, Gurney M.
    Platelets; 2008 Dec 15; 19(8):605-13. PubMed ID: 19012178
    [Abstract] [Full Text] [Related]

  • 20. COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
    Coy ED, Cuca LE, Sefkow M.
    Bioorg Med Chem Lett; 2009 Dec 15; 19(24):6922-5. PubMed ID: 19880317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.